Lead Investigator: Dipak Kotecha, University of Birmingham
Title of Proposal Research: Big data and meta-analytic approaches for better phenotyping in atrial fibrillation and heart failure
Vivli Data Request: 6541
Funding Source: None
Potential Conflicts of Interest: Professor Kotecha reports grants from the National Institute for Health Research (NIHR CDF-2015-08-074 RATE-AF; NIHR HTA-130280 DaRe2THINK), the British Heart Foundation (PG/17/55/33087 and AA/18/2/34218), EU/EFPIA Innovative Medicines Initiative (BigData@Heart 116074), and the European Society of Cardiology. These grants will not present any conflict of interest when this research is published or presented.
Educational grants from Boehringer Ingelheim/BMS-Pfizer Alliance/Bayer/Daiichi Sankyo/Boston Scientific, the NIHR/University of Oxford Biomedical Research Centre and British Heart Foundation/University of Birmingham Accelerator Award (STEEER-AF NCT04396418), Amomed Pharma and IRCCS San Raffaele/Menarini (Beta-blockers in Heart Failure Collaborative Group NCT0083244). These grants will not present any conflict of interest when this research is published or presented.
Personal fees from Bayer (Advisory Board), AtriCure (Speaker fees), Amomed (Advisory Board), Protherics Medicines Development (Advisory Board) and Myokardia (Advisory Board). These grants will not present any conflict of interest when this research is published or presented.
Summary of the Proposed Research:
Atrial fibrillation is a disorder causing an irregular heart rhythm, and heart failure is where the heart doesn’t pump as well as it should. These two conditions are common and lead to patients having more hospital admissions and poorer health in general. Both are commonly seen together and the amount of people expected to develop these conditions in the future will rise considerably. Currently, there is limited information available on how to treat patients with both atrial fibrillation and heart failure. When both conditions are present standard medications appear to work less well and it is unclear why. In order for us to find suitable treatments that will work well in these patients we need to gather information from previous studies. We have already shown that this can be helpful in patients with atrial fibrillation and heart failure. The aim of this study is to collate a large amount of information in patients with atrial fibrillation and heart failure, and to use advanced computer programmes to help us identify more effective treatments.
Requested Studies:
Randomized Evaluation of Dabigatran Etexilate Compared to warfarIn in pulmonaRy Vein Ablation: Assessment of an Uninterrupted periproCedUral alntIcoagulation sTrategy (The RE-CIRCUIT Trial)
Data Contributor: Boehringer Ingelheim
Study ID: NCT02348723
Sponsor ID: 1160.204
RELY-ABLE Long Term Multi-center Extension of Dabigatran Treatment in Patients With Atrial Fibrillation Who Completed the RE-LY Trial and a Cluster Randomised Trial to Assess the Effect of a Knowledge Translation Intervention on Patient Outcomes
Study ID: NCT00808067
Sponsor ID: 1160.71
Data Contributor: Boehringer Ingelheim
Randomized Evaluation of Long Term Anticoagulant Therapy (RE-LY) Comparing the Efficacy and Safety of Two Blinded Doses of Dabigatran Etexilate With Open Label Warfarin for the Prevention of Stroke and Systemic Embolism in Patients With Non-valvular Atrial Fibrillation: Prospective, Multi-centre, Parallel-group, Non-inferiority Trial (RE-LY Study)
Data Contributor: Boehringer Ingelheim
Study ID: NCT00262600
Sponsor ID: 1160.26
Update: This data request was withdrawn on 5-Jun-2023 by the researcher.